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Chronic myelomonocytic leukemiaThe differentiation of human peripheral blood monocytes into macrophages can be reproduced ex vivo by
culturing the cells in the presence of colony-stimulating factor 1 (CSF1). Using microarray proﬁling to explore
the role of microRNAs (miRNAs), we identiﬁed a dramatic decrease in the expression of the hematopoietic
speciﬁc miR-142-3p. Up- and down-regulation of this miRNA in primary human monocytes altered
CSF1-induced differentiation of monocytes, as demonstrated by changes in the expression of the cell surface
markers CD16 and CD163. One of the genes whose expression is repressed by miR-142-3p encodes the tran-
scription factor Early Growth Response 2 (Egr2). In turn, Egr2 associated with its co-repressor NGFI-A (Nerve
Growth Factor-Induced gene-A) binding protein 2 (NAB2) binds to the pre-miR-142-3p promoter to negatively
regulate its expression. Interestingly, the expression of miR-142-3p is abnormally low in monocytes from
patients with the most proliferative forms of chronic myelomonocytic leukemia (CMML), and miR-142-3p
re-expression in CMML dysplastic monocytes can improve their differentiation potential. Altogether, miR-142-3p
which functions in amolecular circuitry with Egr2 is an actor of CSF1-induced differentiation of humanmonocytes
whose expression could be altered in CMML.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Human peripheral blood monocytes are seminal effectors and
regulators of the host inﬂammatory and innate immune responses.
They are produced in the bone marrow, circulate in the blood, and
enter into tissues under inﬂammatory conditions to give rise to a variety
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l rights reserved.environment [1]. Ex vivo exposure of monocytes to colony-stimulating
factor 1 (CSF1), also known as macrophage-colony stimulating factor
(M-CSF), induces their differentiation into macrophages.
CSF1 signals through the CSF1 receptor tyrosine kinase (CSF1R),
encoded by the C-FMS proto-oncogene [2], to trigger a series of phos-
phorylation cascades that mediate this cellular response [3,4]. The in-
teraction of CSF1 with its receptor generates waves of phosphatidyl
inositol 3-kinase (PI3K)/Akt activation, leading after 2–3 days to the
activation of caspases that actively contribute to the formation of rest-
ing macrophages [3,5,6]. These signaling pathways may also connect
CSF1R to the transcription machinery [7]. For example, MafB and c-Maf
could prevent the proliferation of differentiated monocytes and macro-
phages [8] whereas Egr2 (early growth response 2, also known as
Krox20) activates macrophage-speciﬁc genes such as C-FMS, in cooper-
ation with Spi-1/PU.1 [9–11].
A role for microRNAs (miRNAs) in the complex regulatory network
that governs monocyte differentiation into macrophages has been
identiﬁed. When inducing the differentiation of human monocytes
into macrophages with a so-called M1, pro-inﬂammatory phenotype,
GM–CSF provokes a decrease in the expression of miR-223, miR-15a,
and miR-16, which may contribute to this speciﬁc phenotype [12].
ThemiRNAs involved in the CSF1-induced differentiation ofmonocytes,
leading to macrophages with a M2 anti-inﬂammatory phenotype, are
less known, even though C-FMS expression has been shown to be
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transcription factor RUNX1 and by miR-155 that targets Spi-1/PU.1
and C/EBPβ [13,14].
We report here that miR-142-3p is a regulator of CSF1-induced
macrophage differentiation and forms with Egr2 a positive feedback
loop. More precisely, exposure of human monocytes to CSF1 induces a
decrease in the expression of miR-142-3p, which enhances the expres-
sion of the transcription factor Egr2. In turn, Egr2 interacts with the
miR-142-3p promoter to down-regulate its expression. The expres-
sion of this miRNA can be down-regulated in monocytes from patients
with chronic myelomonocytic leukemia (CMML), a myeloproliferative/
myelodysplastic syndrome which main characteristic is the accumu-
lation of monocytes in peripheral blood, bone marrow and spleen
[15].
2. Material and methods
2.1. Cell culture, differentiation and treatment
The human erythroleukemic K562 cell line (American Type Culture
Collection, Manassas, VA, USA) and human puriﬁed monocytes were
grown in RPMI 1640 Glutamax medium (BioWhittaker, Cologne,
Germany) supplemented with 10% fetal calf serum (BioWhittaker),
penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin
B (0.25 μg/mL) (BioWhittaker). Mononucleated cells were selected
by Ficoll Hypaque (Eurobio, Les Ulis, France). The AutoMacs system
(Miltenyi Biotec, Cologne, Germany) was then used to perform cell
enrichment. Positive selection with CD14+ magnetic isolation kit
(Miltenyi Biotec) was performed for monocyte enrichment for the
purpose of miR-142-3p and Egr2 expression analyses. Concerning
monocyte transfection, negative selection was used (Miltenyi Biotec).
Monocytes were plated at 0.5 × 106 cells/mL and incubated for differ-
ent times in the presence or absence of CSF1 (100 ng/ml) (Miltenyi
Biotec), at 37 °C in a 5% CO2 humidiﬁed atmosphere. Cell morphology
was analyzed on cytospin slide preparations stained with May–
Grünwald–Giemsa.
2.2. Constructs
A fragment of 1210 bp, encompassing the entire human Egr2 3′UTR,
was PCR-ampliﬁed with the following sense (5′-GATGAGACTCAGGCTG
ATACACCAGCTCCC-3′) and antisense (5′-ATTGTTGAAAAGTATTTATTTA
CACTATAGTCACAAACCATCC-3′) primers using standard procedures
and a proofreading polymerase (Platinum Pfu) (Invitrogen, Carlsbad,
CA, USA). The cDNA clone, which contains the full length of Egr2 3′
UTR was used as template. The PCR product was sub-cloned into the
pCR 2.1 vector (Invitrogen). The Egr2 3′UTR inserts were removed
from the pCR 2.1 plasmid by XbaI digestion and ligated into a XbaI site
located downstream of the ﬁreﬂy luciferase (f-luc) reporter gene
(pGL3-Promoter vector) (Promega, Madison, WI, USA) driven by a
202 bp 5′ ﬂanking region from human SV40 gene. The authenticity
and orientation of the inserts relative to the luciferase gene were con-
ﬁrmed by sequencing. The resulting plasmids were designated pEgr2
3′UTR. Point mutations in miR-142-3p seed region were introduced
with the QuikChange site-directed mutagenesis kit II (Stratagene,
Santa Clara, CA, USA) by using the pEGR2 3′UTR vector as template,
and by following the protocol provided in the kit. Mutagenesis
was performed with the following sense (5′-GCACAACGACCCC
GAGCACCCTTTCCTGTCC-3′) and antisense (5′-GGACAGGAAAGGGT
GCTCGGGGTCGTTGTGC-3′) primers. Mutations were conﬁrmed by
sequencing.
2.3. MicroRNA microarray analysis
In order to prepare RNA samples for miRNA microarray or miRNA
quantiﬁcation, total RNA enriched with small RNAs was isolated usingmirVana miRNA isolation kit (Ambion, Austin, TX, USA) according to
the manufacturer's protocol. RNA preparations from monocytes and
CSF1-treated monocytes were sent to LC Sciences™ (Houston, TX,
USA) for miRNA microarray analysis using the mParaﬂo microﬂuidic
chips and detailed process can be found at http://www.lcsciences.
com. The microarray data reported in this study have been deposited
in the Gene Expression Omnibus (GEO), http://www.ncbi.nlm.nih.
gov/geo/ (accession number GSE31306).
2.4. Flow cytometry analysis
Fluorescence activated cell sorting (FACS) analysis was performed on
untreated or CSF1-treatedmonocytes. In brief, single-cell suspensionwas
prepared and stained with primary antibodies. The cells were washed
twice in PBS and re-suspended in PBS/0.1% bovine serum albumin (BSA
1%). Antibodies were added and incubated on ice. Antibodies CD16-PE,
CD14-PE, CD163-PE, andCD71-APCwere purchased fromBDBiosciences.
Flow cytometry was performed on LSRII (Becton Dickinson, Franklin
Lakes, NJ, USA) using DIVA software (Becton Dickinson), and automati-
cally compensations were applied. The results were analyzed using
FlowJO software.
2.5. RNA isolation, reverse transcription, quantitative real-time PCR, 5′-RACE
Total RNA was extracted with TRI Reagent® (Ambion, Austin, TX,
USA) and reverse transcribed with random primer (Promega). Quantita-
tive real-time PCR was performed in triplicates in an Applied Biosystems
7500 Fast thermocycler (Foster City, CA, USA). For Pri-miRNA expression,
commercial ready-to-use primers/Taqman probe mixes were used
(Applied Biosystems) (pri-miR-142: Hs03303162_pri). Expression
of mature miR-142-3p was determined using miRNA-speciﬁc quan-
titative real-time PCR assay (Applied Biosystems, 000464). Human
cyclophilin A (Hs99999904_m1*) and RNU6B (Applied Biosystems,
0001093) were used as endogenous controls. For EGR2 expression,
quantitative real-time PCR was performed using SyBr Green detec-
tion protocol as outlined by the manufacturer. Brieﬂy, 15 ng of
total complementary DNA, 50 nM of each primer and 1× SyBr
Green mix were used in a total volume of 20 μl. The human speciﬁc
forward and reverse primers were: L32, 5′-TGTCCTGAATGTGGTCA
CCTGA-3′ and 5′-CTGCAGTCTCCTTGCACACCT-3′ used as a standard-
izing control, EGR2, 5′-GCCCTTCGCCTGTGACTACT-3′ and 5′-GTGG
CGCTTCCTCTCATCA-3′. L32 was used as internal control. 5′ Rapid
ampliﬁcation of cDNA ends (5′-RACE) was carried out using the
TaKaRa 5-Full RACE Kit (TaKaRa Bio. Inc., Shiga, Japan) according to
the manufacturer's instructions. Two rounds of 5′ RACE-PCR were
performed. The 5′ RACE product was gel puriﬁed, cloned into the
pMD19-T vector (TaKaRa Bio. Inc.), then sequenced. The human 5′
end-phosphorylated RT primer was 5′-CCACATGTCCAG-3′. The spe-
ciﬁc primers used for RACE were the following: A1, 5′-AGACAG
GCAGCCGCACATGAGAA-3′; S1, 5′-TTCGGAGATCACGCCACTGCT-3′;
A2, 5′-CCGACGGGTCCGGAGGACTGA-3′; S2, 5′-CCACCATCTTCCTCG
GCGCTC-3′.
2.6. Western-blot analysis
Untreated or CSF1-treated monocytes were re-suspended in
cooled lysis buffer (1% SDS, 1 mM sodium vanadate, 10 mM Tris
pH 7.4, protease inhibitor cocktail). Samples were incubated on ice
for 30 min. Total protein extracts were boiled in Laemmli buffer
then separated by SDS-PAGE and electro-blotted to a nitrocellulose
membrane. Equivalent loading of lanes was controlled with Ponceau
Red Stain (data not shown). Membranes were blocked in 1× PBS-T
(0.1%) and fat-free dry milk (5%) during 1 h at room temperature.
Membranes were incubated with anti-Egr2 (Aviva Systems Biology
LLC, San Diego, CA, USA), anti-Egr1 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-HSC70 (Santa Cruz Biotechnology) or anti-Actin
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night, then washed three times in 1× PBS-T (0.1%) during 10 min
each. The secondary anti-rabbit antibodies conjugated with horse-
radish peroxidase were added, and the membranes were incubated
at room temperature during 1 h. Membranes were washed three
times in 1X PBS-T (0.1%) during 10 min each. ECL Western blotting
reagent kit (Millipore, Billerica, MA, USA) was used for protein
detection.2.7. Transfections
Partially double-stranded RNAs thatmimicmiR-142-3p endogenous
precursor or anti-miR™ miRNA inhibitor and miRNA negative control
(scrambled) were obtained from Ambion. Five millions of monocytes or
3 to 5 × 106 of K562 cells were transfected with 500 pmol of precursor
or siRNA, by nucleoporation, according to the manufacturer's protocol
(Amaxa, Lonza, Cologne, Germany). For the luciferase activity assay,
K562 cells were co-transfected by nucleoporation with 1 μg of mutated
or non-mutated pEgr2 3′UTR vector and 100 ng of pCMV-β-Gal vector.
Cells were harvested 24 h post-transfection, assayed with Luciferase
Assay System and normalized with Beta-Galactosidase Enzyme Assay
System (Promega) according to the manufacturer's instructions. The
siRNA, synthesized by Invitrogen, targets human Egr2 (siEgr2) (sense:
5′-GGAUCUCCCAUAUCCCAGCAGCUUU-3′). A luciferase siRNA (siLUC)
was used as a negative control (sense: 5′-CUUACGCUGAGUACUUCG
Att-3′).2.8. ChIP assays
Brieﬂy, 5 × 106 (or 0.5 × 106 for ChIP with anti-Me3H3K4) of
treated and untreated monocytes were ﬁxed with 1% formaldehyde
to cross-link DNA with proteins, lysed and sonicated to obtain DNA
fragments of 200–1000 bp. After pre-clearing with salmon sperm
DNA/protein A agarose beads, the samples underwent immunopre-
cipitation with antibodies speciﬁc to Egr2, NAB2, IgG, IgA (Santa
Cruz Biotechnology), Me3H3K4 (Upstate Biotechnology, Lake Placid,
NY, USA), or no antibody (Control ChIP) at 4 °C overnight. Beads were
washed, protein/DNA complexes eluted, then cross-links reversed by
heating at 65 °C overnight. After RNA and protein digestions, DNA
was puriﬁed on a spin column (NucleoSpin Extract II: Macherey-
Nagel, Düren, Germany). For sequential ChIP assays, the primary immu-
noprecipitation (IP) was done using Egr2 or NAB2 antibody. The
immunoprecipitated complexes were eluted with ChIP buffer. The
eluate from Egr2 or NAB2 IP was re-immunoprecipitated with the
antibody corresponding to the other protein. Quantization by quantita-
tive real-time PCR of co-immunoprecipitated pre-miR-142 promoter
fragments, encompassing the putative Egr2 binding site, was performed
in triplicate using the SYBR green dye detection method with the fol-
lowing primers, designed by the Primer Express software (Applied
Biosystems), 5′-ACCCTCAATGCCCTGAGTCA-3′ (forward) and 5′-CGTG
GCACCAGCTCCAA-3′ (reverse); input corresponding to total sonicated
DNA was used as cell number control. Delta–delta Ct values of each
immunoprecipitated sample were normalized with those obtained
from the ampliﬁcation of their respective input and by subtracting the
values obtained in the corresponding samples incubated without
antibodies.2.9. Statistical analysis
Mann–Whitney U test and two-tailed t-test were used for statistical
analysis. Differences were considered signiﬁcant when p was less than
.05. In all cases, * represents p less than .05; **, p less than .01; and ***,
p less than .001.3. Results
3.1. MiR-142-3p is down-regulated during human macrophage
differentiation
In order to identify miRNAs that could be involved in CSF1-driven
differentiation of human monocytes into macrophages, we sorted pe-
ripheral blood monocytes from healthy donors and treated these cells
during six days with CSF1 to generate resting macrophages, identiﬁed
by cytologic (not shown) and phenotypic criteria (Supplemental Fig. 1).
We then compared by microarray analysis the miRNA proﬁle in mono-
cytes and derived macrophages. Clustering analysis showed signiﬁcant
changes in the expression of 88 miRNAs. Among those, 43 miRNAs
showed an increased expression whereas 45 were decreased (Fig. 1
and Supplemental Table 1) (http://www.ncbi.nlm.nih.gov/geo/ (acces-
sion number GSE31306)). We focused our investigation on miR-142-
3p, whichwas themost down-regulatedmiRNAs in this analysis. Quan-
titative real-time PCR validated the differentiation-associated gradual
and dramatic decrease in miR-142-3p expression upon CSF1-induced
differentiation of monocytes into macrophages (Fig. 1).
To get insights into the role of miR-142-3p in CSF1-induced differ-
entiation of monocytes, we expressed a synthetic pre-miRNA and an
antagomir in these primary cells before exposure to CSF1. The
changes induced in miR-142-3p were validated 24 h later, and the
changes induced in surface marker expression were examined 48 h
later. Modulation of miR-142-3p expression affected some of the phe-
notypic changes associated with CSF1-induced differentiation. Down-
regulation of miR-142-3p with an antagomir provoked a decrease in
the expression of CD16 and CD163 without affecting the differentiation
associated changes in CD14 and CD71 expression (Fig. 2A). Conversely,
enforced expression of miR-142-3p induced an increase in the expres-
sion of CD16 andCD163 at the cell surface (Fig. 2B). Enforced expression
of miR-142-3p also down-regulated the expression of 2 of 30 myeloid
speciﬁc genes screened by quantitative real-time PCR after 24 h of
CSF1 treatment (Supplemental Table 2), namely CUX1 (cut-like homeo-
box 1) and KLF4 (Krüppel-like factor 4) genes (Fig. 2C).
These results argued for a contribution of miR-142-3p to CSF1-
induced differentiation of primary monocytes into macrophages.
3.2. MiR-142-3p inhibits Egr2
In silico analysis identiﬁed a miR-142-3p complementary seed
sequence in the 3′UTR of Egr2 gene (Fig. 3A). Egr2 gene encodes a tran-
scription factor involved in myeloid cell differentiation. More precisely,
Egr2 inhibits granulocytic differentiation by repressing GFI-1 transcrip-
tion factor expression, while promoting monocyte differentiation in
cooperation with Spi-1/PU.1 by increasing the expression of cFMS
gene [9,10]. In turn, CSF1 enhances the expression of Egr2 in peripheral
blood monocytes [11].
Using quantitative real-time PCR analysis, we observed that exposure
of primary monocytes to CSF1 induced a rapid increase in Egr2 gene
expression, reaching a peak 2 h after the beginning of cell treatment,
then decreasing within a few hours to return to its basal level (Fig. 3B).
The corresponding protein, which was hardly detected in untreated
monocytes, accumulated within a few hours upon CSF1 treatment
(Fig. 3C, upper panels). Meanwhile, the expression of miR-142-3p and
that of its precursor pri-miR-142-3p progressively declined (Fig. 3B).
To determine whether Egr2 was a direct target of miR-142-3p, re-
porter plasmids containing the Egr2 3′UTR with the binding site for
miR-142-3p and the mutated internal control were co-transfected
with pre-miR-142-3p into K562 cells. MiR-142-3p produced from
pre-miR-142-3p repressed the expression of luciferase fused to the
WT Egr2 3′UTR (Fig. 3D), and failed to repress the Egr2 3′UTR
containing amutatedmiR-142-3p seed sequence (Fig. 3A, D), indicating
that miR-142-3p directly targets the Egr2 3′UTR. Expression of an
antagomir speciﬁcally targeting miR-142-3p in primary human
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Fig 1. CSF1 induces down-regulation of miR-142-3p in human primary CD14+ mono-
cytes. (A)Heatmap representation of differentially regulatedmiRNAs inmonocytes before
and after 6 days after CSF1 exposure. Red denotes high expression and green low expres-
sion. Total RNA was divided in 7 samples. Hybridization experiments were performed by
the LC Sciences™ company. (B) MiR-142-3p expression (quantitative real-time PCR) in
CSF1-treated monocytes after 2, 4, and 6 days of treatment. Data are means ± standard
deviation of the values from one representative experiment performed in triplicate out
of three.
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mRNA and protein levels, respectively (Fig. 3E, F). Conversely, transient
overexpression of the pre-miR-142-3p in these cells (Supplemental
Fig. 2) decreased the expression of Egr2 mRNA or protein (Fig. 3C
lower panels, G). The effect of overexpressed miR-142-3p on Egr2
protein levels was observed 3 h after CSF1 treatment, when Egr2
protein level reaches a peak. Egr1 expression was also downregulated
(Supplemental Fig. 3), conﬁrming the association of both genes, partic-
ularly in macrophage differentiation [9].
Altogether, these data indicate that miR-142-3p down-regulates
Egr2 expression through speciﬁc 3′UTR binding site.
3.3. MiR-142-3p expression is regulated by Egr2
TESS software was used to analyze all possible binding sites of Egr2.
One canonical 5′-GCGGGGGCGG-3′ Egr2 binding site within 997 bp of
the transcriptional start of the human miR-142 gene was found. 5′
RACE-PCR analysis performed on genomicDNA fromhumanmonocytes
identiﬁed the putative transcription start site and the promoter region
(Fig. 4A and Supplemental Fig. 4A, B). It was already reported using
human K562 cells overexpressingmiR-223 [16], with a slight difference
concerning the location of the putative transcription start site. There-
fore, the Egr2 binding site is located in the human promoter miR-142
gene.
In order to investigate whether Egr2 physically interacted with the
pre-miR-142 promoter region in vivo, we carried out ChIP analyses on
CSF1-treated human monocytes. Sonicated chromatin prepared from
these cells were subjected to chromatin immunoprecipitation using
anti-Egr2. After crosslink reversal, a segment of the pre-miR-142promoter
containing the Egr2 binding site, increasing 2 h after the beginning of
CSF1 treatment, was ampliﬁed by quantitative real-time PCR (Fig. 4B).
The transcription partner of Egr2, NAB2 (NGFI-A-binding protein 2),
which regulates the transactivation activity of Egr2 [17,18] and behaves
as a co-repressor, was also bound in pre-miR-142 promoter (Fig. 4C),
and ChIP/re-ChIP experiments indicated that both proteins were
recruited simultaneously (Fig. 4D). Then we assessed by ChIP the level
of the H3K4 trimethylation (Me3H3K4) epigenetic mark that correlates
with mammalian gene activation. A fall in the enrichment of this
histone post-translational modiﬁcation was observed after 1 h of CSF1
treatment (Fig. 4E and Supplemental Fig. 5), correlated with the de-
crease of miR-142-3p and pri-miR-142-3p expression (Fig. 3B).
RNAi-mediated down-regulation of EGR2 in CSF1-treated monocytes
(Fig. 4F) induced a 2-fold increase in miR-142-3p expression (Fig. 4G).
These results indicate that Egr2 and its co-regulator NAB2 interact
with the pre-miR-142 promoter in CSF1-treated human monocytes to
provoke its down-regulation.
Altogether, these data show that a feedback loop between
miR-142-3p and Egr2 is operating during early CSF1-induced macro-
phage differentiation.
3.4. MiR-142-3p is down-regulated in a high number of chronic
myelomonocytic leukemia patients
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/
myeloproliferative syndrome in which monocytes and dysplastic
immature granulocytes accumulate in the bone marrow, peripheral
blood (PB), and spleen [15]. Clonal cytogenetic abnormalities have
been observed in ~30% of the patients, uniparental disomy in more
1940 B. Lagrange et al. / Biochimica et Biophysica Acta 1833 (2013) 1936–1946than 50% of cases, and gene mutations in all the cases in which exome
sequencing was performed ([19,20], and personal data). However,
none of these aberrations is speciﬁc of the disease and how they
contribute to CMML emergence and progression remains a matter of
active investigation (Itzykson et al., submitted).
The expression of miR-142-3p was measured in peripheral blood
monocytes sorted from 103 patients with a CMML and healthy donors
(Supplemental Table 3). This analysis revealed a signiﬁcant lower
level of miR-142-3p in CMML patients compared with healthy donorsm
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7114 16 163CD:(Fig. 5A). The CMML patients were separated into two groups, based
on the distribution of miR-142-3p expression (Supplemental Fig. 6).
The white blood cell count and the monocyte count (Fig. 5B) were
signiﬁcantly higher in CMML patients harboring low level of miR-142-
3p. Since leukocyte count is a negative prognostic factor in this chronic
leukemia [21] (and Itzykson et al., submitted), these results suggest
that the decrease in miR-142-3p expression likely affects the disease
outcome.
Immunoblot analysis indicated that monocytes from CMML patients
with lowmiR-142-3p expressed high levels of Egr2 proteinwhereas the
expression of Egr2 mRNA was similar between CMML patients and
healthy donors (Fig. 5C, D).
Re-expression of miR-142-3p in CMML monocytes through transfec-
tion with a synthetic precursor followed by the exposure of the cells to
CSF1 ex vivo, increased the number of cells with a ﬁbroblast-like shape
that is characteristic of CSF1-driven monocyte differentiation (Fig. 6A),
and increased the expression of CD163 and CD16 at the surface of differ-
entiated cells (Fig. 6B). Altogether, these results indicated that the
dysplastic status of CMML monocytes included a decreased expression
of miR-142-3p and conﬁrmed the contribution of this miRNA to some
phenotypic aspects of CSF1-induced differentiation.
4. Discussion
Our study identiﬁes the contribution of miR-142-3p to CSF1-
induced differentiation of human monocytes and demonstrates that
this miRNA is part of a molecular circuitry that also involves the tran-
scription factor Egr2 (Fig. 7). The decreased expression of miR-142-3p
in the monocytes of the most proliferative CMML patients enforces
the demonstration that these leukemic monocytes are dysplastic
with altered differentiation capabilities.
MiR-142-3p was identiﬁed as a hematopoietic speciﬁc miRNA
[22] and its expression was detected in several hematopoietic cell
lineages [23]. MiR-142-3p expression increases when human primitive
stem/progenitor CD133+ hematopoietic cells differentiate into more
committed CD133− cells [24]. In this context, miR-142-3p directly
represses CD133 expression [25]. In zebraﬁsh, miR-142-3p was in-
volved in the conversion from hematopoietic progenitor cells tomature
erythrocytes [26]. Several functions of miR-142-3p in differentiated
cells have been established, i.e. miR-142-3p restricts the production of
cyclic 3′5′-adenosine monophosphate (cAMP) by targeting adenylyl
cyclase (AC) 9 mRNA in T cells [27] and macrophages [28], negatively
affects interleukin-6 production in dendritic cells exposed to lipopoly-
saccharides [29], and represses the glucocorticoid receptor NR3C1 gene
[30] and the RAC1 human small GTPase [31]. The down-regulation of
miR-142-3p allows the elimination of regulatory T cells induced by
low doses of cyclophosphamide [32]. Interestingly, it was proposed to
introduce miR-142-3p target sequences in constructs used for geneFig. 2. Modulation of miR-142-3p expression provokes immunophenotypic changes
during CSF1-mediated differentiation of normal CD14+ monocytes. (A) Expression
of miR-142-3p, by quantitative real-time PCR, in monocytes 24 h after transfection
with control Anti-miR (Ctrl) or Anti-miR-142-3p (Anti) (left panel). Data are
means ± standard deviation of the values from one representative experiment
performed in triplicate out of three. Monocytes transfected either with control
Anti-miR (Ctrl) or Anti-miR-142-3p (Anti) were treated during 48 h with CSF1. FACS
analysis of CD14, CD71, CD16, and CD163 of corresponding cells is shown (right
panel). Error bars represent standard deviation andwere obtained from three independent
experiments. (B) Expression of miR-142-3p, by quantitative real-time PCR, in monocytes
24 h after transfection with control Pre-miR (Ctrl) or Pre-miR-142-3p (Pre) (left panel).
Data are means ± standard deviation of the values from one representative experiment
performed in triplicate out of three. Monocytes transfected either with control Pre-miR
(Ctrl) or Pre-miR-142-3p (Pre) were treated during 48 h with CSF1. FACS analysis of
CD14, CD71, CD16, and CD163 of corresponding cells are shown (right panel). Error bars
represent standard deviation and were obtained from three independent experiments.
(C) Expression (quantitative real-time PCR) of Cux1 and Klf4 in monocytes, treated with
CSF1 during 24 h of treatment. Black columns represent control pre-miR (Ctrl) transfected
cells whereas grey columns represent pre-miR-142-3p (Pre) transfected cells. Error bars
represent standard deviation and were obtained from four independent experiments.
D 
0 
20 
40 
60 
80 
100 
120 
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (%
 of
 co
nt
ro
l) Ctrl 
Pre*** 
A 
AGGUAUUUCAUCCUUUGUGAUGU - 5miR-142-3p 
AACAAACACUACEgr2 3 UTR 
AACGACCCCGAGEgr2 3 UTRmut
Hours 
R
el
at
iv
e 
fo
ld
 e
xp
re
ss
io
n 
0 
0.5 
1 
1.5 
2 
2.5 
3 
0 1 2 3 4 5 6 7 8 
miR-142-3p 
Egr2 
Pri-miR-142 
B 
G 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
Eg
r2
 r
el
at
iv
e 
ex
pr
es
sio
n *** 
PreCtrl 
E 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
1.8 
2.0 
Eg
r2
 r
el
at
iv
e 
ex
pr
es
sio
n
*** 
Anti Ctrl 
F 
0 
20 
40 
60 
80 
100 
120 
140 
160 *** 
Eg
r2
 e
xp
re
ss
io
n,
 r
el
at
iv
e 
 
to
 c
on
tr
ol
 A
nt
i-m
iR
 (%
)
Anti Ctrl 
Anti Ctrl 
Egr2 
HSC70 
55 
C 
Ctrl 
55 
55 
CSF1 0 1 2 3 4 6 
Egr2 
HSC70 
Hours
Egr2 
HSC70 
Pre
Eg
r2
 e
xp
re
ss
io
n,
 r
el
at
iv
e 
 
to
 c
on
tr
ol
 P
re
-m
iR
  (%
)
0 
100 
200 
300 
400 
500 
600 Ctrl 
Pre
0 2 6 Hours4 3 1 
*** * 
Fig. 3.MiR-142-3p inhibits Egr2. (A) Sites of miR-142-3p seed match in the Egr2 3′UTR, and description of the Egr2 3′UTRmutant (mut). The four nucleotides in site 71 in green font
were mutated from AAAU to GCCG in the Egr2 3′UTR mutant plasmid. (B) Expression (quantitative real-time PCR) of miR-142-3p, Pri-miR-142, and Egr2 in CD14+ monocytes
treated with CSF1. Data are means ± standard deviation of the values from one representative experiment performed in triplicate out of three. (C) CD14+ monocytes were
transfected with control Pre-miR (Ctrl) or Pre-miR-142-3p (Pre). Twelve hours after, monocytes were treated during 6 h with CSF1. Total protein extracts obtained from the
cells were run on a 10% SDS-PAGE, transferred, and probed with anti-Egr2 or anti-HSC70 (loading control). Quantitation of Egr2 protein from three independent experiments is
also shown (lower panel). (D) Luciferase reporter assays were performed by transiently transfecting K562 cells with a control Pre-miR (Ctrl) or a Pre-miR-142-3p (Pre), the indicated
3′UTR luciferase reporter plasmids, and a plasmid producing β-galactosidase. Luciferase values were normalized to β-galactosidase, and the percent of luciferase activity in cells
transfected with Pre-miR-142-3p is presented. Error bars represent standard deviation and were obtained from three independent experiments. (E) Expression of Egr2 by quantitative
real-time PCR in CD14+ monocytes 24 h after transfection with control Anti-miR (Ctrl) or Anti-miR-142-3p (Anti). Error bars represent standard deviation and were obtained from
four independent experiments. (F) Expression of Egr2 by immunoblotting in CD14+monocytes 24 h after transfection with control Anti-miR (Ctrl) or Anti-miR-142-3p (Anti). Total ex-
tracts obtained from the cells were run on a 10% SDS-PAGE, transferred, and probed with anti-EGR2 or anti-HSC70 (loading control) (left panel). Quantitation of Egr2 protein from three
independent experiments is also shown (right panel). (G) Expression of Egr2 (quantitative real-time PCR) in CD14+ monocytes 24 h after transfection with control Pre-miR (Ctrl) or
Pre-miR-142-3p (Pre). Error bars represent standard deviation and were obtained from ﬁve independent experiments.
1941B. Lagrange et al. / Biochimica et Biophysica Acta 1833 (2013) 1936–1946therapy to prevent transgene expression in hematopoietic lineages
while permitting high levels of expression in non-hematopoietic cells
[33].In CSF1-treated human monocytes, we identiﬁed a dramatic
down-regulation of miR-142-3p, as compared to other miRNAs. We
then observed that changes in miR-142-3p expression level could
B0 
2 
4 
6 
8 IgG 
EGR2
0 2 6 Hours 4 
R
el
at
iv
e 
en
ri
ch
m
en
t
0 
1 
2 
3 
4 
5 
6 
7 
IgG 
NAB2
R
el
at
iv
e 
en
ri
ch
m
en
t 
0 3 6 Hours 
C 
0 
1 
2 
3 
4 
R
el
at
iv
e 
en
ri
ch
m
en
t 
D 
m
iR
-1
42
-3
p 
re
la
tiv
e e
xp
re
ss
io
n 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 *** 
G 
A
F
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
0 1 2 3 0 1 2 3 
siLUC 
siEgr2 
Hours 
Eg
r2
 r
el
at
iv
e 
ex
pr
es
sio
n 
siLUC
0 1 2 3 CSF1 
Egr2 
HSC70 
Hours 
siEgr2 
0 1 2 3 
55 
E 
997-GCGGGGGCGG-984 
Egr2 
0
100
200
300
400
500
600
700
800
0 2 6 Hours41 8
M
e3
H
3K
4 
re
la
tiv
e e
nr
ic
hm
en
t  
co
m
pa
re
d 
to
 Ig
A
 
Fig. 4. Egr2 is recruited onto the pre-miR-142 promoter. (A) Schematic representation of the Pri-miR-142 genomic promoter. Arrow: the transcriptional start site. The sequence and
location of the Egr2-binding site are indicated. (B) Chromatin from CD14+ monocytes at different times of induction was immunoprecipitated with an anti-Egr2 or an irrelevant
IgG antibody, and the recovered DNA was submitted to quantitative real-time PCR using pre-miR-142 promoter primers. Data are means ± standard deviation of the values from
one representative experiment performed in triplicate out of three. (C) Chromatin from CD14+ monocytes at different times of induction was immunoprecipitated with an
anti-NAB2 antibody or an irrelevant IgG antibody, and the recovered DNAwas submitted to quantitative real-time PCR using pre-miR-142 promoter primers. Data are means ± standard
deviation of the values from one representative experiment performed in triplicate out of three. (D) ChIP-re-ChIP showing the occupancy of Egr2-NAB2 on the pre-miR-142 promoter.
Antibodies used for the ﬁrst and second IP are indicated. Data are means ± standard deviation of the values from one representative experiment performed in triplicate out of three.
(E) Chromatin from CD14+ monocytes at different times of induction was immunoprecipitated with an anti-Me3H3K4 antibody or an irrelevant IgA antibody, and the recovered DNA
was submitted to quantitative real-time PCR using pre-miR-142 promoter primers. Data are means ± standard deviation of the values from one representative experiment performed in
triplicate out of three. (F) CD14+monocytes transfected either with control siRNA (siLUC) or siEgr2 were treatedwith CSF1. The expression of Egr2 (RQ-PCR)was examined inmonocytes
24 h after transfection (upper panel). Error bars represent standard deviation andwereobtained from three independent experiments. Total extracts obtained from the cellswere run on a
10% SDS-PAGE, transferred, and probed with the anti-Egr2 antibody. HSC70 was used as loading control (lower panel). (G) Expression of miR-142-3p (quantitative real-time PCR) in
CD14+ monocytes transfected either with control siLUC or siEgr2 treated for 6 h with CSF1. Error bars represent standard deviation and were obtained from ﬁve independent
experiments.
1942 B. Lagrange et al. / Biochimica et Biophysica Acta 1833 (2013) 1936–1946
C 
3 4 5 6 7
55
40
55
1 2
*  
Egr2 
Actin 
CMML Ctrl 
A 
P < 0.0001 
Lo
g(m
iR
-14
2-3
p e
xp
re
ssi
on
) 
0 
2 
4 
6 
8 
Healthy  
donors 
CMML 
patients 
B 
P = 0.007 
W
hi
te
 b
lo
od
 c
el
ls 
(G
/L
) 
miR-142-3p 
low 
miR-142-3p 
high 
50 
100 
150 
200 
5 
10 
15 
20 
0 
P = 0.003 
M
on
oc
yt
es
 (G
/L
) 
miR-142-3p 
low 
miR-142-3p 
high 
50 
100 
150 
200 
4 
6 
8 
2 
0 
10 
1 2 
Ctrl 
0 
200 
400 
600 
800 
m
iR
-1
42
-3
p 
le
ve
l (r
ela
tiv
e t
o R
N
U
6B
 
1,
00
0) 
3 4 5 6 7 
CMML 
n
d 
Healthy  
donors 
CMML 
patients 
N.S. 
Lo
g(E
gr
2 e
xp
re
ssi
on
) 
0 
2 
4 
6 
D 
0 
2 
4 
6 
8 
10 
12 
0 50 100 150 200 250 300 350 400 450 
r = - 0.099 
Egr2 mRNA relative expression (  1,000) 
m
iR
-1
42
-3
p 
re
la
tiv
e e
xp
re
ss
io
n 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(   
1,0
00
) 
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1943B. Lagrange et al. / Biochimica et Biophysica Acta 1833 (2013) 1936–1946affect the differentiation process, as demonstrated by the altered
expression of the surface markers CD16 and CD163. These observa-
tions led us to explore the possibility that miR-142-3p may regulate
the expression of genes involved in the response to the cytokine, and
in silico analyses led us to focus on Egr2 gene and identify a feedback-
induced regulatory mechanism of Egr2 involving miR-142-3p. EGRproteins are transcription factors involved in both lymphoid and
myeloid hematopoiesis [34]. Egr2 inhibits granulocytic differentiation
by repressing GFI-1 expression and promotes the expression of CSF1R
gene in cooperation with Spi-1/PU.1 [9,10]. In turn, CSF1 induces a rapid
increase in Egr2 expression in monocytes [11]. The Egr2/miR-142-3p
regulation is reminiscent of a recently described miR-17-92 circuitry
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1944 B. Lagrange et al. / Biochimica et Biophysica Acta 1833 (2013) 1936–1946driven by Spi-1/PU.1 transcription factor during earlier steps of the
monocyte/macrophage differentiation [35], and of the one involving
miR-223 and NFI-A during human granulopoiesis [36].
The decrease expression of miR-142-3p in monocytes of patients
with a CMML did not correlate with mutations in TET2, SRSF2 and
ASXL1 genes, the three most frequently mutated genes in CMML
(Itzykson et al., submitted), nor with any other less frequent gene mu-
tations (data not shown). Themechanisms that decrease the expression
of miR-142-3p in leukemic monocytes remain to be identiﬁed. The cor-
relation between a decreased expression of miR-142-3p in CMML
monocytes and the number of white blood cells and monocytes in the
peripheral blood could indicate that abnormally activated signaling
pathways that are responsible for the proliferative form of the disease,
play a role in miR-142-3p expression decrease. Interestingly, miR-142-
3p expression is increased in peripheral blood mononucleated cells
from patients with a chronic myelogenous leukemia [37], and in blast
cells of those with a B-cell [38] or a T-cell [39] acute lymphoblastic
leukemia. On the contrary miR-142-3p expression is decreased in
mantle cell lymphoma cells [40] and in blast cells from patients
with acute myeloid leukemia [41]. In this later context, miR-142-3p
was demonstrated to suppress the expression of cyclin T2 (CCNT2)
and TGF-β activated kinase 1/MAP3K7 binding protein 2 (TAB2) [41].Again, the molecular mechanisms responsible for the deregulated ex-
pression of miR-142-3p in various hematological malignancies remain
to be identiﬁed.
To the best of our knowledge, miR-142-3p is the ﬁrst miRNA
whose role in monocyte terminal differentiation upon CSF1 exposure
has been identiﬁed. Our initial microarray analysis indicates up- and
down-regulation of several other miRNAs in CSF1-treated monocytes,
some of them being probably involved in this process. In addition, the
miR-142-3p/Egr2 circuitry depicted in differentiating monocytes may
play a role at earlier steps of hematopoietic cell differentiation, when
Egr2 is involved in lineage choices, and miR-142-3p may target other
genes involved in hematopoietic cell differentiation. Better understanding
of the networks that implicate miR-142-3p will indicate the importance
of its deregulated expression observed in several hematological diseases.
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